Search Results - "Okubo, Tomomi"

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study by Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Tani, Joji, Kariyama, Kazuya, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Aoki, Tomoko, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Arai, Taeang, Okubo, Tomomi, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Koji, Hiasa, Yoichi, Kudo, Masatoshi

“…It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint…”
Get full text

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease by Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Kato, Keizo, Abe, Hiroshi, Ono, Hirotaka, Kawano, Tadamichi, Yoshida, Yuji, Tanabe, Tomohide, Okubo, Tomomi, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Emoto, Naoya, Nagao, Mototsugu, Inagaki, Kyoko, Fukuda, Izumi, Sugihara, Hitoshi, Iwakiri, Katsuhiko

“…Nonalcoholic fatty liver disease (NAFLD) is related to subclinical atherosclerosis. However, whether the severity of the disease (or which histopathological…”
Get full text

Relationship between serum vitamin D level and sarcopenia in chronic liver disease by Okubo, Tomomi, Atsukawa, Masanori, Tsubota, Akihito, Yoshida, Yuji, Arai, Taeang, Iwashita, Ai‐Nakagawa, Itokawa, Norio, Kondo, Chisa, Iwakiri, Katsuhiko

“…Aim Although the association of vitamin D with primary sarcopenia has been extensively investigated, its relationship with secondary sarcopenia in patients…”
Get full text

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment by Okubo, Hironao, Atsukawa, Masanori, Okubo, Tomomi, Ando, Hitoshi, Nakadera, Eisuke, Ikejima, Kenichi, Nagahara, Akihito

“…Glecaprevir is a substrate for organic anion-transporting polypeptide (OATP) 1B1/1B3, which transports bilirubin. Hyperbilirubinemia is an adverse event during…”
Get full text

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib by Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Fukunishi, Shinya, Ohama, Hideko, Kawata, Kazuhito, Tani, Joji, Nakamura, Shinichiro, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Takaaki, Tanaka, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi

“…We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma…”
Get full text

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients by Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, Casadei-Gardini, Andrea

“…The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive…”
Get full text

Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease by Okubo, Tomomi, Atsukawa, Masanori, Tsubota, Akihito, Ono, Hiroki, Kawano, Tadamichi, Yoshida, Yuji, Arai, Taeang, Hayama, Korenobou, Itokawa, Norio, Kondo, Chisa, Iwakiri, Katsuhiko

“…Sarcopenia frequently and progressively occurs in patients with chronic liver disease. This study aimed to clarify the relationship between vitamin D levels…”
Get full text

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C by Yoshida, Yuji, Atsukawa, Masanori, Kondo, Chisa, Kitamura, Michika, Shioda-Koyano, Kaori, Kawano, Tadamichi, Ono, Hiroki, Hayama, Korenobu, Okubo, Tomomi, Arai, Taeang, Itokawa, Norio, Iwakiri, Katsuhiko

“…Although eliminating HCV can prevent hepatocellular carcinoma (HCC), some patients develop HCC even after obtaining sustained virologic response (SVR)…”
Get full text

Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease by Atsukawa, Masanori, Kondo, Chisa, Kawano, Tadamichi, Okubo, Tomomi, Arai, Taeang, Nakagawa-Iwashita, Ai, Itokawa, Norio, Iwakiri, Katsuhiko

“…Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis and hepatocellular carcinoma. Interferon-based treatment was previously the only…”
Get full text

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib by Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Aoki, Tomoko, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Hiasa, Yoichi, Kudo, Masatoshi

“…We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC)…”
Get full text

Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease by Kawano, Tadamichi, Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Toyoda, Hidenori, Takaguchi, Koichi, Tani, Joji, Morishita, Asahiro, Hiraoka, Atsushi, Mikami, Shigeru, Ishikawa, Toru, Okubo, Hironao, Watanabe, Tsunamasa, Okubo, Tomomi, Arai, Taeang, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Iwakiri, Katsuhiko

“…Nalfurafine hydrochloride, a selective κ-opioid receptor agonist has been approved for pruritus in patients with chronic liver disease. However, not all…”
Get full text

Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization by Atsukawa, Masanori, Tsubota, Akihito, Hatano, Masaru, Kondo, Chisa, Shioda, Kaori, Ohno, Hiroki, Kawano, Tadamichi, Hayama, Korenobu, Arai, Taeang, Nakagawa‐Iwashita, Ai, Itokawa, Norio, Kaneko, Keiko, Yoshida, Yuji, Koeda, Mai, Okubo, Tomomi, Yamamoto, Teppei, Yamamoto, Takeshi, Taniai, Nobuhiko, Yoshida, Hiroshi, Kanazawa, Hidenori, Shimizu, Wataru, Iwakiri, Katsuhiko

“…Aim Portopulmonary hypertension (PoPH) is a well‐known complication of liver cirrhosis. The aim of this study was to clarify the pulmonary hemodynamics and the…”
Get full text

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice by Tanaka, Takaaki, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kosaka, Hisashi, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, Kudo, Masatoshi, Kumada, Takashi

“…Background/Aim Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh…”
Get full text

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study by Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Kumada, Takashi

“…Aim This study aimed to investigate the utility of C-reactive protein (CRP) and alpha-fetoprotein (AFP) in immunotherapy (CRAFITY) score in hepatocellular…”
Get full text

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease by Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Kawano, Tadamichi, Koeda, Mai, Yoshida, Yuji, Tanabe, Tomohide, Okubo, Tomomi, Hayama, Korenobu, Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Kawamoto, Chiaki, Hatori, Tsutomu, Emoto, Naoya, Iio, Etsuko, Tanaka, Yasuhito, Iwakiri, Katsuhiko

“…Although the presence of nonalcoholic fatty liver disease (NAFLD) is known to be related to subclinical atherosclerosis, the relationship between the severity…”
Get full text

Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis by Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Hiasa, Yoichi, Kudo, Masatoshi

“…Background/Aim Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u‐HCC) classified…”
Get full text

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial by Okubo, Tomomi, Atsukawa, Masanori, Tsubota, Akihito, Ono, Hiroki, Kawano, Tadamichi, Yoshida, Yuji, Arai, Taeang, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Iwakiri, Katsuhiko

“…Background: Sarcopenia worsens patient prognoses in chronic liver disease. This study aimed to elucidate the effects of vitamin D supplementation on skeletal…”
Get full text

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B by Itokawa, Norio, Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Toyoda, Hidenori, Takaguchi, Koichi, Hiraoka, Atsushi, Senoh, Tomonori, Koeda, Mai, Yoshida, Yuji, Okubo, Tomomi, Arai, Taeang, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Kondo, Chisa, Iwakiri, Katsuhiko

“…Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its…”
Get full text

A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C by Atsukawa, Masanori, Tsubota, Akihito, Kondo, Chisa, Uchida-Kobayashi, Sawako, Takaguchi, Koichi, Tsutsui, Akemi, Nozaki, Akito, Chuma, Makoto, Hidaka, Isao, Ishikawa, Tsuyoshi, Iwasa, Motoh, Tamai, Yasuyuki, Tobari, Maki, Matsuura, Kentaro, Nagura, Yoshihito, Abe, Hiroshi, Kato, Keizo, Suzuki, Kenta, Okubo, Tomomi, Arai, Taeang, Itokawa, Norio, Toyoda, Hidenori, Enomoto, Masaru, Tamori, Akihiro, Tanaka, Yasuhito, Kawada, Norifumi, Takei, Yoshiyuki, Iwakiri, Katsuhiko

“…Evaluating liver fibrosis is crucial for disease severity assessment, treatment decisions, and hepatocarcinogenic risk prediction among patients with chronic…”
Get full text

Usefulness of autotaxin for the complications of liver cirrhosis by Shao, Xue, Uojima, Haruki, Setsu, Toru, Okubo, Tomomi, Atsukawa, Masanori, Furuichi, Yoshihiro, Arase, Yoshitaka, Hidaka, Hisashi, Tanaka, Yoshiaki, Nakazawa, Takahide, Kako, Makoto, Kagawa, Tatehiro, Iwakiri, Katsuhiko, Terai, Shuji, Koizumi, Wasaburo

“…Autotaxin (ATX) has been reported as a direct biomarker for estimating the evaluation of liver fibrosis. But available data on ATX as a useful biomarker for…”
Get full text